Related Experiment Video
Updated: Jun 27, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Early treatment of multiple sclerosis to prevent neurologic damage
1MS Comprehensive Care Center, Stony Brook University Medical Center, Stony Brook, NY 11794, USA. pcoyle@notes.cc.sunysb.edu
Abstract:
Multiple sclerosis (MS) involves ongoing accumulating CNS damage. Precisely which environmental factors trigger onset and progression of the disease are not known. However, clinical trials indicate benefits from early use of disease-modifying therapies (DMTs). All the completed clinically isolated syndrome trials (CHAMPS, ETOMS, BENEFIT, PRECISE) reported significant suppression of subsequent relapse and MRI lesion formation from use of DMT at the first relapse. This article reviews data on early treatment. Such an approach requires the ability to recognize clinically isolated syndrome features that indicate a diagnosis of MS.
Insights
Early treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) at the first relapse significantly reduces subsequent relapses and MRI lesion formation. Recognizing early symptoms of MS is crucial for timely intervention.
Area of Science:
- Neurology
- Immunology
- Neuroscience
Background:
- Multiple sclerosis (MS) is characterized by progressive central nervous system (CNS) damage.
- Environmental triggers for MS onset and progression remain unidentified.
- Early intervention with disease-modifying therapies (DMTs) shows promise in clinical trials.
Purpose of the Study:
- To review data supporting the benefits of early treatment in MS.
- To highlight the importance of identifying early clinical indicators for MS diagnosis.
Main Methods:
- Review of completed clinical trials for clinically isolated syndrome (CIS).
- Analysis of data from CHAMPS, ETOMS, BENEFIT, and PRECISE trials.
- Evaluation of treatment outcomes, including relapse rates and MRI lesion formation.
Main Results:
- Early use of DMTs at the first relapse significantly suppressed subsequent relapses.
- Early DMT administration led to a significant reduction in MRI lesion formation.
- Clinical trials consistently demonstrated benefits of early therapeutic intervention.
Conclusions:
- Initiating DMTs upon the first relapse of MS is associated with improved outcomes.
- Early diagnosis of MS, based on recognizing CIS features, is critical for effective management.
- Prompt treatment strategies can mitigate disease progression and neurological damage.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:22Alzheimer's Disease: Treatment
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...